Axsome Therapeutics, Inc. shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers at the 2026-06-05 meeting.
“Proposal 3: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers. The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 37,818,384 777,937 366,155 4,815,060”
Shareholder Votes
Axsome Therapeutics, Inc. shareholders approved Ratification of Appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-05 meeting.
“Proposal 2: Ratification of Appointment of Deloitte & Touche LLP. The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 43,278,147 14,407 484,982 0”
Shareholder Votes
Axsome Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2026-06-05 meeting.
“Proposal 1: Election of Class II Directors. The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding the election of the Class II directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Mark Saad 28,675,654 10,286,822 4,815,060 Susan Mahony, Ph.D., MBA 29,892,131 9,070,345 4,815,060”
Earnings Releases
Axsome Therapeutics, Inc. reported first quarter of 2026 results: revenue $191.2 million, net income $(64.5) million, EPS $(1.26) per share.
“Total net product revenue was $191.2 million for the first quarter of 2026, representing 57% year-over-year growth.”
Debt Financings
Axsome Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $570.0 million with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. at Term SOFR adjusted secured overnight financing rate plus a margin of 4.75% maturing five years from the Closing Date.
“The Loan Agreement provides for loans in an aggregate principal amount of up to $570.0 million, consisting of (i) a first lien senior secured term loan in an aggregate principal amount of $120.0 million funded to the Company on the Closing Date, (ii) a $180.0 million senior secured term loan which is available to the Company at the Company’s option”
Earnings Releases
Axsome Therapeutics, Inc. reported first quarter of 2024 results: revenue $75.0 million, net income $68.4 million, EPS $(1.44) per share.
“Total net product revenue for the first quarter of 2024 was $75.0 million, representing 160% year-over-year growth.”
Earnings Releases
Axsome Therapeutics, Inc. reported the fourth quarter and full year of 2023 results: revenue $71.5 million, net income $(2.08) per share, EPS $(2.08) per share.
“Total net product revenues were $71.5 million and $204.9 million for the fourth quarter and full year of 2023, representing year-over-year growth of 193% and 309%, respectively.”
Earnings Releases
Axsome Therapeutics, Inc. reported the full year of 2023 results: revenue $204 million.
“Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.”
Earnings Releases
Axsome Therapeutics, Inc. reported the fourth quarter of 2023 results: revenue $71 million.
“Axsome expects total product revenue to be approximately $71 million and $204 million for the fourth quarter and full year of 2023, respectively.”
Earnings Releases
Axsome Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue Total product revenue for the third quarter of 2023 was $57.8 million, net income Net loss for the third quarter of 2023 was $62.2 million, EPS $(1.32) per share.
“Third Quarter 2023 Financial Highlights • Total product revenue for the third quarter of 2023 was $57.8 million, representing 244% year-over-year growth, and consisting of net product sales of $57.1 million and royalty revenue of $0.7 million. Total product revenue for the comparable period in 2022 was $16.8 million. • Auvelity ® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023. There were no Auvelity sales in the comparable 2022 period as the product was launched in October 2022. • Sunosi ® net product revenue was $20.1 million for the third quarter of 2023, representing 20% year-over-year growth, and consisting of $19.4 million in net product sales and $0.7 million in royalty revenue associated with Sunosi sales in out-licensed territories. Sunosi net product revenue for the comparable period in 2022 was $16.8 million. • Total cost of revenue was $6.5 million for the third quarter of 2023. Tot”
Dr. Susan Mahony was appointed as Director at Axsome Therapeutics, Inc..
“The Board of Directors (the “Board”) of Axsome Therapeutics, Inc. (the “Company”), increased the size of the Board from four to five directors, and on October 8, 2023 appointed Dr. Susan Mahony as a director to be effective as of October 10, 2023 (the “Effective Date”).”
Earnings Releases
Axsome Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $46.7 million, net income $(1.54) per share.
“--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter”
Auditor Changes
Axsome Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.
“On June 22, 2023, Ernst & Young LLP (“Ernst & Young”) was informed that the Committee approved Ernst & Young’s dismissal as the Company’s independent registered public accounting firm with such dismissal to be effective as of June 30, 2023.”
Auditor Changes
Axsome Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor.
“On June 22, 2023, the Audit Committee (the “Committee”) of the Board of Directors of Axsome Therapeutics, Inc. (“we,” “our,” “us,” or the “Company”) approved the engagement of Deloitte & Touche LLP (“Deloitte”), to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023 with such appointment to be effective as of June 30, 2023.”
Shareholder Votes
Axsome Therapeutics, Inc. shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s named executive officers at the 2023-06-02 meeting.
“Proposal 4: Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s named executive officers. The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 26,607,318 628,910 524,331 6,637,733”
Shareholder Votes
Axsome Therapeutics, Inc. shareholders approved Proposal to approve the 2023 Employee Stock Purchase Plan (ESPP) at the 2023-06-02 meeting.
“Proposal 3: A proposal to approve the ESPP. The Company’s stockholders approved the adoption of the ESPP. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 27,347,369 357,216 55,974 6,637,733”
Shareholder Votes
Axsome Therapeutics, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-02 meeting.
“Proposal 2: Ratification of Appointment of Ernst & Young LLP. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 34,061,821 113,392 223,079 0”
Shareholder Votes
Axsome Therapeutics, Inc. shareholders approved Election of Class II Director at the 2023-06-02 meeting.
“Proposal 1: Election of Class II Director. The Company’s stockholders elected the following director to serve as a Class II director until the 2026 annual meeting of stockholders and until their successor is duly elected and qualified. The votes regarding the election of the Class II director were as follows: Director Votes For Votes Withheld Broker Non-Votes Mark Saad 17,685,595 10,074,964 6,637,733”
Earnings Releases
Axsome Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $94.6 million, net income net loss of $11.2 million, EPS $(0.26) per share.
“2023 Financial Results and Corporate Update Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK, May 8, 2023 (GLOBE NEWSWIRE) -- Axsome”
Earnings Releases
Axsome Therapeutics, Inc. reported Full year 2022 results: revenue $50.0 million, net income Net loss of $187.1 million, EPS $(4.60).
“Fourth Quarter 2022 Financial Highlights • Total net sales were $24.4 million and $50.0 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. Auvelity was launched on October 19, 2022 and had U.S. net sales of $5.2 million for the fourth quarter of 2022. No Auvelity sales were reported by Axsome for the 2021 comparable period reflecting the timing of the Auvelity approval and launch. Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May 2022 and in certain international markets in November 2022. Therefore no Sunosi sales were reported by Axsome for the 2021 comparable periods. • Total cost of product sales were $2.3 million and $5.2 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. • Research and development (R&D) expenses were $14.7 million”
Earnings Releases
Axsome Therapeutics, Inc. reported Fourth quarter 2022 results: revenue $24.4 million, net income Net loss of $61.2 million, EPS $(1.41).
“Fourth Quarter 2022 Financial Highlights • Total net sales were $24.4 million and $50.0 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. Auvelity was launched on October 19, 2022 and had U.S. net sales of $5.2 million for the fourth quarter of 2022. No Auvelity sales were reported by Axsome for the 2021 comparable period reflecting the timing of the Auvelity approval and launch. Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May 2022 and in certain international markets in November 2022. Therefore no Sunosi sales were reported by Axsome for the 2021 comparable periods. • Total cost of product sales were $2.3 million and $5.2 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. • Research and development (R&D) expenses were $14.7 million”
Material Agreements
Axsome Therapeutics, Inc. entered into License Agreement with Atnahs Pharma UK Limited (Pharmanovia) valued at €62.0 million ($66.2 million) (effective 2023-02-21).
“On February 21, 2023, Axsome Malta Ltd., a Malta limited company (“Axsome Malta”), a wholly-owned subsidiary of Axsome Therapeutics, Inc. (the “Company”), entered into a License Agreement (the “License Agreement”) with Atnahs Pharma UK Limited (Pharmanovia), a company organized and existing under the laws of England and Wales (the “Licensee”), pursuant to which Axsome Malta will license certain Licensed Intellectual Property (as defined in the License Agreement) to the Licensee and grant an exclusive license to Licensee in the Territory (as defined in the License agreement to include Europe and certain countries in the Middle East and Africa) for use of the Licensed Intellectual property for the development and commercialization of the Company’s Licensed Products (as defined in the License Agreement and which includes the Company’s product Sunosi®).”
Material Agreements
Axsome Therapeutics, Inc. amended Third Amendment with Hercules Capital, Inc. valued at $350,000,000 (effective 2023-01-09).
“On January 9, 2023, Axsome Therapeutics Inc., a Delaware corporation (the “Company”), entered into a Third Amendment (the “Third Amendment”) to its Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc.”
M&A Transactions
Axsome Therapeutics, Inc. completed an acquisition involving Jazz Pharmaceuticals plc (closed 2022-11-14).
“The final closing contemplated by the Purchase Agreement (i.e., the conveyance of the ex-U.S. assets) occurred on November 14, 2022”
Earnings Releases
Axsome Therapeutics, Inc. reported financial results for the three months ended September 30, 2022.
“On November 7, 2022, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2022 and provided an update on the Company’s operations.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.